Expert discussions are underway on the lifting of bans on cannabis-derived drugs in Japan. The government is set to create the environment needed to allow for the utilization of such medicines by embracing this policy in its annual “honebuto” paper,…
HOME > TRENDS
TRENDS
-
Global Pharmas Mull Excluding Japan from In-Licensing Deals on Annual Revision Fears, Softer Yen
January 26, 2016
-
Takeda’s Exit from Diabetes Research a Symbolic Move under Weber Leadership
January 20, 2016
-
Teva JV Deal Marks Turning Point in Takeda’s Japanese Business
January 6, 2016
-
“Huge Seller” Re-Pricing Targeting Hep C Drugs Will Dampen Innovative Market
December 9, 2015
-
Peak Sales Forecast for New Drugs Listed in 2015 Exceeded 840 Billion Yen with Big Contribution from Hep C Treatments
December 7, 2015
-
AG Shares Reach 50-60% in 1 Year; Confidence in Quality Encourages Dominance Even without Market Lead
November 30, 2015
-
Full-Year Forecasts for Domestic Market Down vs Previous Year; Major Makers Struggling Even in Year without NHI Price Revision
November 11, 2015
-
Shift to Specialty - 5: Eisai, Ajinomoto Jump on Specialty Bandwagon to Seek Efficiency in GI Biz
October 30, 2015
-
Drug Makers’ Payments to Medical Institutions Dip for Second Year: Jiho Tally
September 15, 2015
-
Transformation of ARB Market Spurred by AGs, Power Map Changing Fast as Brand-Name Drugs Falter
September 4, 2015
-
Japan Drug Makers See Rising Overseas Sales Ratios in April-June
August 11, 2015
-
IFN-Free Drugs Upending Hepatitis C Market Landscape
July 17, 2015
-
3 Major Japan Makers Shed 1,300 Jobs amid Redundancy Programs
June 30, 2015
-
“80% Generic” Era Would Further Accelerate Contraction of Market for Long-Listed Drugs
June 29, 2015
-
Top-4 Japanese Drug Makers Report Widely Different Financial Results for FY2014
May 22, 2015
-
Will 5,000 Contract Sales Reps Be Just a Way Station for a Higher Goal Beyond?
April 24, 2015
-
Global Drug Sales Rose 8.8% to US$936.5 Billion in 2014: IMS Health
April 3, 2015
-
Development Tie-Ups with Immune Checkpoint Inhibitors Increase; to Maximize Value through Combination
March 27, 2015
-
Most Global Products on Track to Clear Their FY2014 Sales Forecasts; Abilify Posting Sales of 650 Billion Yen
March 16, 2015
-
Will SGLT-2 Inhibitors Catch On? Breakout Will Require Accumulation of Data
February 25, 2015
ページ
“The Tesla and SpaceX CEO sent an email to employees at both companies on Tuesday saying everyone must spend 40 hours per week in the office. ‘If you don’t show up, we will assume you have resigned. The more senior…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…